PE20242008A1 - Compuestos de pirazina como inhibidores de flt3 - Google Patents

Compuestos de pirazina como inhibidores de flt3

Info

Publication number
PE20242008A1
PE20242008A1 PE2024001491A PE2024001491A PE20242008A1 PE 20242008 A1 PE20242008 A1 PE 20242008A1 PE 2024001491 A PE2024001491 A PE 2024001491A PE 2024001491 A PE2024001491 A PE 2024001491A PE 20242008 A1 PE20242008 A1 PE 20242008A1
Authority
PE
Peru
Prior art keywords
compounds
independently
flt3
pyrazine compounds
flt3 inhibitors
Prior art date
Application number
PE2024001491A
Other languages
English (en)
Spanish (es)
Inventor
David Sperandio
Thomas Butler
Thorsten A Kirschberg
Xiaodong Wang
Nan-Horng Lin
Solomon B Ungashe
Neil Howard Squires
Ravindra B Upasani
Thu Phan
James T Palmer
Amna Trinity-Turjuman Adam
Yongli Su
Original Assignee
Biomea Fusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/040953 external-priority patent/WO2023027966A1/en
Application filed by Biomea Fusion Inc filed Critical Biomea Fusion Inc
Publication of PE20242008A1 publication Critical patent/PE20242008A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2024001491A 2021-12-30 2022-12-29 Compuestos de pirazina como inhibidores de flt3 PE20242008A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163295494P 2021-12-30 2021-12-30
US202263316939P 2022-03-04 2022-03-04
US202263364860P 2022-05-17 2022-05-17
PCT/US2022/040953 WO2023027966A1 (en) 2021-08-24 2022-08-19 Pyrazine compounds as irreversible inhibitors of flt3
US202263386772P 2022-12-09 2022-12-09
PCT/US2022/054270 WO2023129667A1 (en) 2021-12-30 2022-12-29 Pyrazine compounds as inhibitors of flt3

Publications (1)

Publication Number Publication Date
PE20242008A1 true PE20242008A1 (es) 2024-10-03

Family

ID=85225088

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024001491A PE20242008A1 (es) 2021-12-30 2022-12-29 Compuestos de pirazina como inhibidores de flt3

Country Status (11)

Country Link
US (2) US11945785B2 (cg-RX-API-DMAC7.html)
EP (1) EP4370506A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025502748A (cg-RX-API-DMAC7.html)
KR (1) KR20240128987A (cg-RX-API-DMAC7.html)
AU (1) AU2022426699A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242316A1 (cg-RX-API-DMAC7.html)
IL (1) IL313670A (cg-RX-API-DMAC7.html)
MX (1) MX2024008057A (cg-RX-API-DMAC7.html)
PE (1) PE20242008A1 (cg-RX-API-DMAC7.html)
TW (1) TW202340177A (cg-RX-API-DMAC7.html)
WO (1) WO2023129667A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
JP7891524B2 (ja) 2021-08-11 2026-07-16 バイオメア フュージョン,インコーポレイテッド 真性糖尿病に対するメニン-mll相互作用の共有結合性阻害剤
EP4525873A1 (en) * 2022-05-17 2025-03-26 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
WO2024155719A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction

Family Cites Families (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
ATE250932T1 (de) 1999-07-16 2003-10-15 Warner Lambert Co Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
CA2439113C (en) 2001-04-09 2009-11-24 Fuji Photo Film Co., Ltd. Coloring composition for image formation and method for improving ozone resistance of color image
JP2002309116A (ja) 2001-04-09 2002-10-23 Fuji Photo Film Co Ltd アゾ化合物、着色組成物、インク組成物、及びインクジェット記録方法
JP4406515B2 (ja) 2001-04-09 2010-01-27 富士フイルム株式会社 アゾ化合物、着色組成物、インク組成物、及びインクジェット記録方法
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
JP2003292859A (ja) 2002-01-30 2003-10-15 Fuji Photo Film Co Ltd インク組成物、インクジェット記録方法
JP3844338B2 (ja) 2002-02-01 2006-11-08 富士写真フイルム株式会社 インクセット、インクカートリッジ、記録方法、プリンター及び記録物
JP2004059687A (ja) 2002-07-26 2004-02-26 Fuji Photo Film Co Ltd 着色組成物、インクジェット記録用インク、インクジェット記録方法、感熱記録材料、カラートナー、およびカラーフィルター
JP4213922B2 (ja) 2002-08-12 2009-01-28 富士フイルム株式会社 インクジェット記録用インク及びインクセット、並びにインクジェット記録方法
JP2004083610A (ja) 2002-08-22 2004-03-18 Fuji Photo Film Co Ltd インクセット、インクカートリッジ、記録方法、プリンター及び記録物
JP2004099802A (ja) 2002-09-11 2004-04-02 Fuji Photo Film Co Ltd 画像形成用着色組成物、インクジェット記録用インクおよびインクジェット記録方法
JP4895341B2 (ja) 2004-07-08 2012-03-14 富士フイルム株式会社 アゾ色素、インクジェット記録用インク、感熱記録材料、カラートナー、カラーフィルター、インクジェット記録方法、インクカートリッジ及びインクジェットプリンター
PL1981863T3 (pl) 2006-01-26 2013-03-29 Boehringer Ingelheim Int Sposób wytwarzania pochodnych chinazoliny podstawionych przez ugrupowanie aminokrotonyloaminowe
JP2007203642A (ja) 2006-02-02 2007-08-16 Fujifilm Corp インクジェット記録用セット、及びインクジェット記録方法
JP2008013499A (ja) 2006-07-06 2008-01-24 Sankyo Co Ltd 5−シアノニコチンアミド誘導体
US7741385B2 (en) 2006-10-31 2010-06-22 Hewlett-Packard Development Company, L.P. Ozone stable ink-jet inks
JP2009139810A (ja) 2007-12-10 2009-06-25 Konica Minolta Business Technologies Inc 電子写真用トナー
MX2011011875A (es) 2009-05-08 2011-12-08 Astellas Pharma Inc Compuesto de carboxamida heterociclica diamino.
SG175711A1 (en) 2009-05-18 2011-12-29 Orion Corp Protease inhibitors
AR078173A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Bifeniloximetil dihidro oxazolopirimidinonas sustituidas, su preparacion y su uso
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
JP2014005206A (ja) 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
AU2011323484B2 (en) 2010-11-01 2016-10-06 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as Syk modulators
DK2799431T3 (en) 2011-12-28 2018-03-26 Fujifilm Corp Hitherto unknown nicotinamide derivatives or salts thereof
HUE033177T2 (en) 2012-01-17 2017-11-28 Astellas Pharma Inc Pyrazine carboxamide compound
WO2013142382A1 (en) 2012-03-22 2013-09-26 Genosco Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
WO2013157540A1 (ja) 2012-04-17 2013-10-24 富士フイルム株式会社 含窒素複素環化合物またはその塩
WO2014012467A1 (zh) 2012-07-20 2014-01-23 中国人民解放军军事医学科学院毒物药物研究所 间二芳基苯胺类或吡啶胺类化合物、其制备方法及医药用途
WO2015056683A1 (ja) 2013-10-16 2015-04-23 富士フイルム株式会社 含窒素複素環化合物の塩またはその結晶、医薬組成物およびflt3阻害剤
WO2015062929A1 (en) 2013-10-29 2015-05-07 Dystar Colours Distribution Gmbh Acid dyes, process for the production thereof and their use
EP2868709A1 (en) 2013-10-29 2015-05-06 DyStar Colours Distribution GmbH Metal free acid dyes, process for the production thereof and their use
EP2868710A1 (en) 2013-10-29 2015-05-06 DyStar Colours Distribution GmbH Metal free acid dyes, process for the production thereof and their use
US20200332369A1 (en) 2014-01-27 2020-10-22 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
HUE049437T2 (hu) 2014-02-04 2020-09-28 Astellas Pharma Inc Hatóanyagként heterociklusos diamino-karboxamid vegyületet tartalmazó gyógyászati készítmény
WO2015182628A1 (ja) 2014-05-28 2015-12-03 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物
DK3169671T3 (da) 2014-07-17 2019-09-23 Sunshine Lake Pharma Co Ltd 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft
WO2016015604A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
WO2016015597A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CN105439879B (zh) 2014-08-07 2018-08-10 天津法莫西医药科技有限公司 一种反式-4-二甲胺基巴豆酸盐酸盐的制备方法
WO2016023217A1 (zh) 2014-08-15 2016-02-18 安润医药科技(苏州)有限公司 喹唑啉衍生物、其制备方法、药物组合物和应用
JP6257782B2 (ja) 2014-08-22 2018-01-10 富士フイルム株式会社 Flt3変異陽性癌を処置するための医薬組成物、変異型flt3阻害剤およびそれらの応用
EP3233902B1 (en) 2014-12-18 2020-09-09 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor
KR20170105021A (ko) 2015-01-28 2017-09-18 아스테라스 세이야쿠 가부시키가이샤 피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체
RU2017140923A (ru) 2015-04-27 2019-05-27 Астеллас Фарма Инк. Стабилизированная фармацевтическая композиция
JP2018104290A (ja) 2015-04-28 2018-07-05 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物
CN106267234B (zh) 2015-06-26 2020-04-10 上海市计划生育科学研究所 含有非核苷类逆转录酶抑制剂的阴道环及其制备方法
KR20180023968A (ko) 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법
SMT202300074T1 (it) 2015-07-03 2023-05-12 Astellas Pharma Inc Composizione farmaceutica stabile per somministrazione orale
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US10308658B2 (en) 2015-10-19 2019-06-04 Sunshine Lake Pharma Co., Ltd. Salt of EGFR inhibitor, crystalline form and uses thereof
WO2017078049A1 (ja) 2015-11-04 2017-05-11 アステラス製薬株式会社 ジアミノヘテロ環カルボキサミド化合物を有効成分とするがん免疫治療用、及び/又は、免疫活性化用医薬組成物
BR112018009463A8 (pt) 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
US9920033B2 (en) 2015-11-14 2018-03-20 Calitor Sciences, Llc Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
WO2017083789A1 (en) 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
JP2019014653A (ja) 2015-11-27 2019-01-31 アステラス製薬株式会社 がん免疫を介したがん治療方法
TWI623316B (zh) 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
EP3436014A4 (en) 2016-03-29 2019-11-27 Astellas Pharma Inc. COMBINATION THERAPY FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA
CN109562176A (zh) 2016-04-15 2019-04-02 费利克斯疗法公司 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
WO2017218365A1 (en) 2016-06-16 2017-12-21 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
CN106083821B (zh) * 2016-06-22 2019-01-11 上海皓元生物医药科技有限公司 一种3,5-二取代-吡嗪-2-甲酰胺化合物的合成方法
ES2925564T3 (es) 2016-07-29 2022-10-18 Rapt Therapeutics Inc Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
WO2018049271A1 (en) 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
EP3512519A1 (en) 2016-09-14 2019-07-24 Gilead Sciences, Inc. Syk inhibitors
CA3040348A1 (en) 2016-10-19 2018-04-26 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
JPWO2018079570A1 (ja) 2016-10-26 2019-09-19 アステラス製薬株式会社 安定な医薬組成物
CN106589055B (zh) 2016-11-03 2020-07-28 清华大学 取代的细胞酰二肽类化合物及其制备方法和用途
AR110273A1 (es) 2016-11-30 2019-03-13 Pharmacyclics Llc Inhibidores de tirosina cinasa de bruton
CN108419436B (zh) 2016-12-09 2021-05-04 深圳市塔吉瑞生物医药有限公司 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
CN108250200A (zh) 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
KR20190128646A (ko) 2017-02-21 2019-11-18 압토스 바이오사이언시스 인코포레이티드 혈액 종양 환자들의 치료 방법
GB201704267D0 (en) 2017-03-17 2017-05-03 Genome Res Ltd Novel biomarker
EP3879269A3 (en) 2017-03-20 2021-11-17 Celcuity Inc. Methods of measuring signaling pathway activity for selection of therapeutic agents
WO2018183762A1 (en) 2017-03-29 2018-10-04 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer
KR20190129889A (ko) 2017-03-31 2019-11-20 노파르티스 아게 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
WO2018200465A1 (en) 2017-04-24 2018-11-01 Ohio State Innovation Foundation Recombinant egfl7, egfl7 antibodies, and uses thereof
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Flt3に特異的な抗体およびその使用
IL271946B (en) 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
CN109251182A (zh) 2017-07-13 2019-01-22 广东东阳光药业有限公司 取代脲衍生物的盐及其在药物中的应用
PT3658148T (pt) 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
EP3673907A4 (en) 2017-08-23 2020-08-19 ONO Pharmaceutical Co., Ltd. CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT
CA3076915A1 (en) 2017-09-27 2019-04-04 AI Therapeutics, Inc. Therapeutic methods relating to hsp90 inhibitors
CA3019207A1 (en) 2017-09-28 2019-03-28 The Governing Council Of The University Of Toronto Methods and compositions for inhibiting mutant egfr signaling
AU2018353150B2 (en) 2017-10-18 2024-06-06 Epizyme, Inc. Methods of using EHMT2 inhibitors in treating or preventing blood disorders
US20200287515A1 (en) 2017-10-24 2020-09-10 Kyocera Corporation Composite substrate and acoustic wave element using same
WO2019084499A1 (en) 2017-10-27 2019-05-02 Genea Biocells USA (Holdings), Inc. INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION
US11247990B1 (en) 2017-12-07 2022-02-15 Array Biopharma Inc Bicyclic fused pyridine compounds as inhibitors of TAM kinases
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
GB201802307D0 (en) 2018-02-13 2018-03-28 Vib Vzw CD36 antagonists for use in melanoma treatment
US20210255170A1 (en) 2018-03-13 2021-08-19 University Of Iowa Research Foundation Inductive regeneration of the airway by transcriptional factor modulation of glandular myoepithelial stem cells
US11512074B2 (en) 2018-03-28 2022-11-29 Shenzhen Targetrx, Inc. Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereof
CN108392634A (zh) 2018-03-28 2018-08-14 清华大学 B7s1抑制剂在制备肝癌药物中的用途
US11723891B2 (en) 2018-04-12 2023-08-15 Umc Utrecht Holding B.V. Drug combinations for use in the treatment of RAS-mutant cancer
WO2019245269A1 (ko) 2018-06-18 2019-12-26 연세대학교 산학협력단 Flt3 억제제를 유효성분으로 포함하는 만성 골수성 백혈병 약물 내성 억제용 조성물
AU2019299555A1 (en) 2018-07-04 2021-02-25 Cytoimmune Therapeutics, Inc. Compositions and methods for immunotherapy targeting FLT3, PD-1, and/or PD-L1
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
TW202019421A (zh) 2018-07-31 2020-06-01 大陸商蘇州亞盛藥業有限公司 Bcl-2/Bcl-xL抑制劑與化療藥物的組合及其應用
KR20200022712A (ko) 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
JP7201800B2 (ja) 2018-09-30 2023-01-10 メッドシャイン ディスカバリー インコーポレイテッド Flt3およびaxlの阻害剤としての3,9-ジアザスピロ[5,5]ウンデカン系化合物
TW202027749A (zh) 2018-10-12 2020-08-01 日商富士軟片股份有限公司 急性骨髓性白血病用抗腫瘤劑
JPWO2020090969A1 (ja) 2018-10-31 2021-09-16 富士フイルム株式会社 抗腫瘍剤を含む医薬組成物の包装体
EP3875090A4 (en) 2018-10-31 2021-12-22 FUJIFILM Corporation PELLET CONTAINING AN ANTITUMOR AGENT
EP3875091A4 (en) 2018-10-31 2021-12-29 FUJIFILM Corporation Pharmaceutical composition containing antitumor agent
WO2020090971A1 (ja) 2018-10-31 2020-05-07 富士フイルム株式会社 抗腫瘍剤を含む錠剤
EP3873462A4 (en) 2018-11-01 2022-08-03 Syros Pharmaceuticals, Inc. CANCER TREATMENT METHODS IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLINE-DEPENDENT KINASE 7 (CDK7)
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US20220017968A1 (en) 2018-12-07 2022-01-20 Cornell University Methods for detecting acute myeloid leukemia
US20200208114A1 (en) 2018-12-10 2020-07-02 The Broad Institute, Inc. Taxonomy and use of bone marrow stromal cell
JP2022510986A (ja) 2018-12-12 2022-01-28 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ ヒアルロン酸およびエピガロカテキン-3-o-没食子酸のコンジュゲートおよびナノ粒子ならびにその使用
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療
US20210386763A1 (en) 2018-12-20 2021-12-16 Novartis Ag Pharmaceutical combinations
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
KR102230721B1 (ko) 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
WO2020172618A2 (en) 2019-02-21 2020-08-27 Bambu Vault Llc Remotely triggered therapy
WO2020171649A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
US12472175B2 (en) 2019-02-26 2025-11-18 Oregon Health & Science University Methods of treating venetoclax-resistant acute myeloid leukemia
TW202045174A (zh) 2019-02-28 2020-12-16 日商富士軟片股份有限公司 組合醫藥
US12630487B2 (en) 2019-03-13 2026-05-19 Otsuka Pharmaceutical Co., Ltd. Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
PL3949952T3 (pl) 2019-04-03 2024-10-14 Astellas Pharma Inc. Kompozycja farmaceutyczna
JP7709384B2 (ja) 2019-04-17 2025-07-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物
JP7822597B2 (ja) 2019-04-17 2026-03-03 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性egfr変異を有するがん細胞に対する抗腫瘍活性を有する化合物
US20200337989A1 (en) 2019-04-25 2020-10-29 Ocular Therapeutix, Inc. Ocular hydrogel tyrosine kinase inhibitor implants
EP3965896A4 (en) 2019-05-09 2023-01-25 The United States Government as Represented by the Department of Veterans Affairs COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
WO2020257671A1 (en) 2019-06-20 2020-12-24 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
EP3991733A4 (en) 2019-06-27 2023-07-05 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
WO2021011871A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
US20220280538A1 (en) 2019-08-14 2022-09-08 Memorial Sloan Kettering Cancer Center Methods of treating p53 mutant cancers using ogdh inhibitors
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
KR20220101606A (ko) 2019-09-12 2022-07-19 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 피리딘 산질화물 및 이의 제조 방법과 용도
WO2021076985A1 (en) 2019-10-16 2021-04-22 University Of Virginia Patent Foundation Ceramide ratios as predictive and therapeutic biomarkers for leukemias
CN114828842A (zh) 2019-10-21 2022-07-29 理森制药股份公司 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
CN112704679B (zh) 2019-10-24 2023-06-06 沈阳药科大学 含高三尖杉酯碱的药物组合物及其应用
CN114901284A (zh) 2019-10-29 2022-08-12 希洛斯医药品股份有限公司 用细胞周期蛋白依赖性激酶7(cdk7)抑制剂治疗生物标志物鉴定的患者的癌症的方法
CA3157196A1 (en) 2019-11-05 2021-05-14 Celgene Corporation Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
US20220387358A1 (en) 2019-11-08 2022-12-08 University Of Virginia Patent Foundation Ceramide analog saclac modulates sphingolipid levels and mcl-1 splicing to induce apoptosis in acute myeloid leukemia
WO2021094827A1 (en) 2019-11-11 2021-05-20 Race Oncology Ltd. Use of bisantrene to treat measurable residual disease in acute myeloid leukemia
WO2021159993A1 (en) 2020-02-14 2021-08-19 Pharmablock Sciences (Nanjing) , Inc. Inhibitors of interleukin-1 receptor associated kinase (irak) /fms-like receptor tyrosine kinase (flt3), pharmaceutical products thereof, and methods thereof
CN113966331B (zh) 2020-03-11 2024-04-12 暨南大学 含脲结构的三芳环化合物及其应用
CN111269149B (zh) 2020-04-08 2022-04-15 南京优氟医药科技有限公司 一种5-(3,3-二甲基胍基)-2-氧代戊酸的生产工艺
CN111358952B (zh) 2020-04-15 2022-03-15 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种抗肿瘤药物组合物及其制剂和应用
CN111558044B (zh) 2020-06-01 2022-02-11 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种包含舒尼替尼的药物组合物及其制剂和应用
CN111808821B (zh) 2020-06-24 2022-06-14 南方医科大学珠江医院 Flt3-nkg2d双靶点car-t的构建与制备
WO2022009235A1 (en) 2020-07-10 2022-01-13 Msn Laboratories Private Limited, R&D Center Process for the preparation of gilteritinib fumarate
CN111760024B (zh) 2020-07-24 2021-12-28 中国药科大学 一种渗透增强型金纳米簇载药靶向制剂及其制法和应用
US12534469B2 (en) 2020-12-15 2026-01-27 Children's Hospital Medical Center Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof
KR102231446B1 (ko) 2021-01-21 2021-03-24 (주) 와이디생명과학 베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물
WO2022173021A1 (ja) 2021-02-12 2022-08-18 公益財団法人がん研究会 ギルテリチニブの種々の変異体に対する適用
CN115429805A (zh) 2021-06-01 2022-12-06 上海交通大学医学院附属瑞金医院 一种抗flt3-itd耐药突变型急性髓系白血病药物
TW202317561A (zh) 2021-07-01 2023-05-01 美商羅曼德生物治療公司 作為治療劑的具有1h—吡唑并[4,3—c]吡啶—6—胺基的化合物
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
EP4401735A4 (en) 2021-09-16 2025-07-16 Lomond Therapeutics Inc COMPOUNDS COMPRISING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS
JP2024538547A (ja) 2021-09-24 2024-10-23 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 薬剤の選択的送達のためのプロドラッグとしての環状過酸化物
CN113861179A (zh) 2021-10-22 2021-12-31 上海应用技术大学 一种新型flt3激酶抑制剂及其合成与应用
CN118055931A (zh) 2021-12-23 2024-05-17 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
WO2023150601A2 (en) 2022-02-02 2023-08-10 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
CN115710281B (zh) 2022-11-14 2024-05-17 南京中医药大学 一种异噁唑并[5,4-b]吡啶类FLT3抑制剂及其制备方法与用途

Also Published As

Publication number Publication date
KR20240128987A (ko) 2024-08-27
TW202340177A (zh) 2023-10-16
US20230339867A1 (en) 2023-10-26
US11945785B2 (en) 2024-04-02
US20240262795A1 (en) 2024-08-08
IL313670A (en) 2024-08-01
EP4370506A1 (en) 2024-05-22
AU2022426699A1 (en) 2024-07-11
MX2024008057A (es) 2024-08-28
CA3242316A1 (en) 2023-07-06
WO2023129667A1 (en) 2023-07-06
JP2025502748A (ja) 2025-01-28

Similar Documents

Publication Publication Date Title
PE20230239A1 (es) Derivado de arilamida con actividad antitumoral
PE20220705A1 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer
ECSP22077299A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k
AR134662A2 (es) Degradadores selectivos del receptor de estrógeno
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20252338A1 (es) Compuesto agonista de receptor thrb y metodo de preparacion
PE20191532A1 (es) Compuestos heterociclicos como inmunomoduladores
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
PE20190705A1 (es) COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
PE20060166A1 (es) Derivados de amida como inhibidores de proteinas de apoptosis (iap)
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
AR077491A1 (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, medicamentos que los contienen y uso de los mismos para el tratamiento de trastornos menopausicos, de fertilidad y otras enfermedades
PE20220704A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos
PE20191784A1 (es) Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
EA202191968A1 (ru) Новые замещенные производные сульфонилмочевины
PE20211447A1 (es) Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas
AR057033A1 (es) Tigeciclina y metodos para preparar 9-nitrominociclina
DK31092A (da) 2-pyrimidinyl-1-piperazin-derivater, deres fremstilling og anvendelse
AR044177A1 (es) Proceso para la preparacion de trans-isomeros de derivados de la difenilazetidinona